S-3304
- Generic Name
- S-3304
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N2O4S2
- CAS Number
- 203640-27-1
- Unique Ingredient Identifier
- BK459F050X
- Background
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 9
- Registration Number
- NCT00078390
- Locations
- ๐บ๐ธ
Lombardi Cancer Center, Washington, District of Columbia, United States
๐บ๐ธScripps Cancer Institute, La Jolla, California, United States
๐บ๐ธUniversity of Kansas Cancer Center, Kansas City, Kansas, United States
S-3304 in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00033566
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase 1 Study of S-3304 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2002-04-10
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 32
- Registration Number
- NCT00033215
- Locations
- ๐บ๐ธ
Roswell Park Cancer Center, Buffalo, New York, United States
๐บ๐ธH. Lee Moffitt Concer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธCleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.